Clearside Biomedical Submits New Drug Application for XIPERE for the Treatment of Macular Edema Associated with Uveitis
pharmaceutical investing Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update
pharmaceutical investing Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA
pharmaceutical investing Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion
Market One Minute Feature on BNN Bloomberg: Omega Pacific Resources Drills to Expand Gold Discovery in BC's Toodoggone
QIMC Engages Global Seismic Processing Leader Earth Signal to Advance Nova Scotia Hydrogen and Helium Multi-Gas Pilot Production Pathway
